Needham Maintains Buy on AtriCure, Raises Price Target to $64

Benzinga Newsdesk www.benzinga.com Positive 72.6%

Neg 0% Neu 0% Pos 72.6%

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $45 to $64.

Comments

No comments yet. Be the first!